A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

Inclusion Criteria:

- Male or female subjects, age 18 years or older

- Histologically or cytologically confirmed NSCLC

- Stage IIIB or Stage IV NSCLC who are not candidates for multimodality treatment and
have received at least 1 line of standard platinum-based therapy:

- Prior systemic regimens must include at least 2 cycles of a platinum-based
therapy and may include platinum therapy used as a radiosensitizer. Maintenance
chemotherapy is allowed.

- Tumors with driver mutations (epidermal growth factor receptor mutation positive
or anaplastic lymphoma kinase fusion oncogene positive) should have had disease
progression or been intolerant to the standard tyrosine-kinase inhibitor (TKI),
and should include a second line TKI where such therapy is available and
indicated.

- Subjects initially treated with a platinum regimen for Stage IIIB disease who
later develop metastatic disease and are re-treated with a platinum regimen are
allowed.

- Histologically or cytologically confirmed urothelial carcinoma.

- Stage IV locally advanced or metastatic urothelial carcinoma with disease progression
during or following platinum-containing chemotherapy or had disease progression within
12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

- Presence of measurable disease per RECIST v1.1

- Availability of an adequate archival tumor specimen or willingness to undergo a
pretreatment tumor biopsy.

- Subjects enrolled in Expansion Cohort 3 must be willing to have 2 on-treatment tumor
biopsies.

- For males and females of child-bearing potential, willingness to use adequate birth
control through 90 days after the last dose of epacadostat or atezolizumab.

Exclusion Criteria:

- Laboratory and medical history parameters not within protocol-defined range.

- Current treatment with an investigational study drug or immunological-based agent for
any reason, or receipt of anticancer medication within 21 days or 5 half-lives
(whichever is longer) before first dose.

- Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-4, anti-PD-1,
anti-PD-L1, and any other antibody or drug specifically targeting T-cell
co-stimulation) or an IDO inhibitor.

- Prior monoclonal antibody within 4 weeks before study Day 1, or has not recovered from
adverse events due to agents administered more than 4 weeks earlier.

- Has an active or inactive autoimmune process.

- Has a history of pneumonitis or idiopathic pulmonary fibrosis, or evidence of
interstitial lung disease.

- Prior radiotherapy within 2 weeks of therapy; Must have recovered from all
radiation-related toxicities, not require corticosteroids, and not have had radiation
pneumonitis.

- Untreated central nervous system (CNS) metastases or CNS metastases that have
progressed after completion of radiotherapy.

- Use of systemic corticosteroids ≤ 2 weeks before Cycle 1 Day 1.

- Currently pregnant or breastfeeding.